Introduction
Chronic renal insufficiency (CRI) is associated with an enhanced oxidative stress, which is assumed to accelerate the progression of renal and cardiovascular disease. 1, 2 Among the numerous uremic toxins, three different compounds show an association with enhanced oxidative stress. (1) Advanced glycation end products (AGEs) accumulate in the organism during experimental and clinical human kidney disease in proportion to the decline in renal function. [3] [4] [5] [6] Besides decreased renal removal, their rise is attributed to enhanced formation, because of carbonyl and oxidative stress. 7, 8 AGEs exert their toxicity both directlyFby alerting the structure/ function of plasma/tissue proteins 9 Fand indirectlyF after their binding to the specific cell surface receptorFincluding RAGE. 10 This interaction leads to the production of reactive oxygen species, which may in turn accelerate formation of AGEs and lipid peroxidation products. (2) Homocysteine (Hcy)Fan independent risk factor of cardiovascular diseaseF accumulates in circulation of patients with CRI.
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Its auto-oxidation results in the production of reactive oxygen radicals, 12 which may contribute to the oxidative stress in the renal disease. (3) Advanced oxidation protein products (AOPPs)F markers of in vivo protein oxidationFaccumulate in CRI patients consistently, as a consequence of impaired renal function. 13 They are supposed to result predominantly from the myeloperoxidase reaction. It still remains questionable whether enhanced oxidative stress may directly potentiate their formation. A high correlation between plasma AOPPs and pentosidineFa chemically defined AGEFwas revealed. 13 Angiotensin-converting enzyme inhibitors (ACEI), alongside their nonhaemodynamic actions, may also improve the defence against oxidative stress. On the one hand, amelioration of the oxidative stress result from the lowered plasma and tissue angiotensin II (AT II) concentrations. On the other hand, ACEI containing a sulphydryl moiety in their molecule act as free radical and oxidant scavengers, while lipid peroxidation is inhibited by both sulphydryl-and non-sulphydryl-containing ACEI. 14 In in vitro studies, ACEI and AT II type 1 receptor antagonists lower formation of AGEs by inhibition of various oxidative steps, as well as the production of reactive carbonyl species. 15 Moreover, in various models of experimental renal disease, an attenuation of oxidative stress following ACEI or AT II receptor 1 antagonist (R1A) administration has been demonstrated. [16] [17] [18] [19] The above-mentioned lines of evidence prompted us to investigate whether the protective actions of ACEI might also be mediated in humans, at least in part, by modulation of the oxidative status. Thus, we followed the plasma levels of AGEs, AOPPs, Hcy and parameters reflecting lipid peroxidation in patients with nondiabetic nephropathy during short-term administration of the ACEI ramipril.
Patients and methods

Patients
A total of 12 newly diagnosed individuals with nondiabetic kidney disease (tubulointerstitial nephritis, n ¼ 8; glomerulonephritis, n ¼ 2; polycystic kidney disease, n ¼ 2) and impaired renal function (serum creatinine 4110 mmol/l or creatinine clearance o60 ml/min) were administered the ACEI ramipril (Tritace, Aventis, France) at a dose of 2.5-5 mg/day over 2 months. Patients' data were compared to two control groups: (1) seven patients with non-diabetic kidney disease (tubulointerstitial nephritis, n ¼ 6; tubulopathy, n ¼ 1) with mild to moderate renal insufficiency (serum creatinine 4110 mmol/l or creatinine clearanceo60 ml/min) on a long-term antihypertensive treatment with diuretics and/or b-receptor blockers; and (2) 10 age-and sex-matched healthy controls (CTRL), who were free of any medication 3 months prior to the investigation. To control for the potential seasonal variation in the investigated data: (1) the patients were recruited into the study within 1 month, (2) they were instructed not to change their eating behaviour during the study, (3) blood samples were taken from patients on conventional therapy also after the 2-month period for determination of the studied parameters. Group characteristics are given in Table 1 .
The study was carried out in accordance with the Declaration of Helsinki and reviewed and approved by the Institutional Ethics Board. All participants signed a written consent. 20 and by competitive ELISA (Penzberg, Germany) with the monoclonal antibody 4G-9 directed against N e -(carboxymethyl)-lysine (CML) as described previously. 21, 22 Advanced oxidation protein products were determined in plasma spectrophotometrically on a microplate reader (MRX, Dynatech, USA) according to Witko-Sarsat et al, 13 malondialdehyde (MDA) levels by HPLC after derivatization with thiobarbituric acid, 23 lipofuscin levels turbidimetrically, 23 Hcy concentrations by employing HPLC, 24 and those of plasma neopterin by ELISA (Immunotech, Marseille, France).
Statistics
Data are given as mean 7 s.d. For statistical evaluation, unpaired Wilcoxon test (CTRL vs patients groups), ANOVA with post hoc least-squares difference test (CTRL vs conventional therapy and rampril) and paired Wilcoxon test (pre-to posttreatment values) were used. w 2 was calculated and a regression analysis was performed. 95% confidence interval (CI) of correlation coefficient was calculated. Po0.05 was considered as significant.
Results
Healthy controls vs newly diagnosed patients with nephropathy
The patients with nondiabetic nephropathy showed a mild to moderate decline of renal function as reflected by serum creatinine, creatinine clearance and cystatin C concentrations (Table 1) . Data on the occurrence of proteinuria (mean: 1.92 7 0.96 g/24 h) and microalbuminuria are given in Table 2 . Patients had mild to moderate hypertension (Table 1) and exhibited higher overall fluorescent AGE levels, as did the chemically defined AGE, CML. Both AGEs accumulated in circulation in proportion to the decline of renal function: fluorescent AGE levels correlated positively with serum creatinine (S-Crea, Figure 1 ) and cystatin C concentrations (r ¼ 0.648, n ¼ 22, Po0.001), and negatively with creatinine clearance (r ¼ À0.689, n ¼ 22, Po0.001). Also, CML levels correlated with cystatin C concentrations, fluorescent AGE levels, as well as with creatinine clearance (n ¼ 22, r ¼ 0.664, Po0.001; r ¼ 0.603, Po0.01; and r ¼ 0.844, Po0.001, respectively). All subjects were normoglycemic (Table 1) , and no relation between AGE-Fl or CML and plasma fasting glucose concentrations was revealed. The mean plasma level of AOPPs was approximately doubled in the patients when compared with healthy subjects (Table 1) . AOPP levels correlated with concentrations of creatinine (Figure 2 ), cystatin C (r ¼ 0.604, n ¼ 21, Po0.01), and fluorescent AGE levels (r ¼ 0.451, n ¼ 21, Po0.05). Lipofuscin levels were increased in the patients' group, while malondialdehyde levels did not differ between the groups (Table 1) . Basal fluorescent AGE ( Figure 3 ) and CML levels (r ¼ 0.645, n ¼ 22, Po0.001) correlated with lipofuscin if both groups were evaluated together. Moreover, a correlation between AOPP and MDA levels was revealed (r ¼ 0.479, n ¼ 21, Po0.05). Plasma Hcy concentrations were elevated in the patient's group (Table 1) : a mild hyperhomocysteinaemia (Hcy 412.5 mmol/l) was observed in 10 out of the 12 patients with nephropathy, while it was evident in only 1/10 control subjects (w 2 ¼ 8.983; Po0.01). Hcy concentrations in both Figure 1 Relation between plasma creatinine concentration and plasma fluorescent advanced glycation end product levels in healthy subjects and newly diagnosed patients with nephropathy. 25 Fwere higher in the patients' group when compared with controls. Moreover, there was a direct relation of neopterin with fluorescent AGE (r ¼ 0.571, n ¼ 22, Po0.01), CML (r ¼ 0.681, n ¼ 22, Po0.001), and AOPP levels (r ¼ 0.500, n ¼ 21, Po0.05), respectively.
Newly diagnosed patients with nephropathy vs conventional treatment group
Means of the investigated basal parameters of the patients assigned to the ramipril treatment group did not differ significantly from those on long-term conventional treatment, except for higher blood pressure and Hcy values (Table 1) . Moreover, microalbuminuria was negative in all except for one patient with mild proteinuria (0.97 g/24 h) ( Table 2 ). Three patients suffered from mild hyperhomocysteinaemia. Its frequency, as evaluated by the w 2 test, did not differ significantly from that observed in the conventional treatment group.
Effect of ramipril administration
As expected, ramipril administration resulted in a decline in blood pressure, without affecting renal function (as evaluated by plasma creatinine, creatinine clearance and cystatin C concentration), during the observed period of 2 months (Table 1 ). In one out of the four proteinuric patients, proteinuria was normalized, one patient reverted to microalbuminuria, and in two a decline was observed (mean: 1.0 7 0.64 g/24 h). In two out of five patients pretreatment microalbuminuria became normal, while in the rest a decline was observed (Table 2) . Plasma fluorescent AGE levels decreased slightly but significantly (by 11%), while the intervention did not influence the CML levels. Moreover, under ramipril treatment, the decline in fluorescent AGE levels was accompanied by a decrease in both AOPPs (by 27%) and MDA concentrations (by 31%). Lipofuscin as well as Hcy levels remained unaffected. A trend towards a rise in plasma neopterin levels was revealed ( Table 1) .
Effect of the conventional treatment
After 2 months, no significant changes in the investigated parameters were observed.
Discussion
Basal data
Plasma and tissue AGE levels reflect the balance of their endogenous production 26 and their removal. This occurs by scavenging in macrophages, 27 as well as by their clearance in the kidney, [4] [5] [6] [7] [8] 28 and liver. 29 In our patients, tobacco smoking as a cause of AGE formation could be excluded, since all participants were nonsmokers. Furthermore, enhanced AGE formation due to diabetes could be disregarded, as all subjects were normoglycaemic and reported a negative history of diabetes in their parents and siblings. A microinflammation as a source of elevation of AGEs seems unlikely, since C-reactive protein concentrations were within the normal range and did not differ between the groups (data not given). Thus, the decline in renal function and the enhanced oxidative stress, as reflected by the rise in AOPP and lipofuscin levels, could account for the rise of AGE levels. Moreover, elevated concentrations of Hcy, which augment the production of reactive oxygen species, 12 could contribute to AGE accumulation. This assumption is supported by the correlation between AOPPs as well as Hcy and CML levels. Elevated concentrations of neopterin in the patients' group point to an activation of monocytes/macrophages as already described in early stages of renal impairment. 30 The neopterin concentration correlated with both the fluorescent AGE and CML levels, corroborating earlier studies of Witko-Sarsat et al, 13 who showed that serum Figure 2 Relation between cystain C concentration and plasma advanced oxidation protein product levels in healthy subjects and newly diagnosed patients with nephropathy. Figure 3 Relation between plasma lipofuscin and fluorescent advanced glycation end product levels in healthy subjects and newly diagnosed patients with nephropathy.
Ramipril affects AGEs and AOPPs K Šebeková et al concentration of the AGE pentosidine correlated with neopterin in patients with impaired renal function.
Effect of ramipril
Treatment with ramipril did not influence the levels of CMLFone of the most prominent AGEs 31 Fbut resulted in a mild decline of fluorescent AGEs. This effect could not be attributed to merely seasonal variations, since the comparison of these data collected after the 2-month period in patients on conventional treatment (diuretics and/or b-blockers) did not show significant changes (Table 1) . To the best of our knowledge there is no prospective data available on the effect of ACEI or AT II R1A administration on plasma AGE levels in human renal disease. However, Forbes et al 32 recently demonstrated that rampiril reduced the accumulation of AGEs and attenuated the accumulation of nitrotyrosineFa marker of protein oxidationFin the model of streptozotocin-induced diabetic nephropathy. Moreover, in our recent long-term study (14 weeks) with losartan in subtotally nephrectomized rats, we could demonstrate less elevated plasma AGE levels as compared to the placebo administered group, probable because of both improved renal function and decreased oxidative stress. 33 In the present human study with ramipril, the observed decline in fluorescent AGE levels could not be credited to the improvement of renal function. Thus, their mild decrease might be a consequence of an ACEI-induced amelioration of the oxidative stress, as indicated by the lowered AOPP and lipofuscin levels. This finding is in accordance with the observational study on haemodialysed patients, in which levels of several antioxidant defences were shown to be higher in enalapril than in nonenalapril-treated patients. 34 Administration of ramipril did not result in a decline in neopterin levels but in a rather small rise of its concentration. This observation is difficult to explain. Among the numerous factors shown to activate monocyte/macrophage function, AT II has been demonstrated to be an important mediator. 35, 36 The unchanged or even slightly elevated neopterin levels during administration of ramipril suggest the role of AT II-independent factors. Interestingly, activation of monocytes/macrophages (as indicated by elevated neopterin, TNF-a and IL-1b levels) in heart failure was also uninfluenced by ACEI, even after administration of a high-dose regimen, reflecting a persistent immune activation by mechanisms other than AT II. 37 Taken together, first evidence is herewith given that administration of the ACEI ramipril to patients with nondiabetic nephropathies results in a slight but significant decline of fluorescent AGE levels, while the CML concentration remains unchanged. These effects of ramipril are accompanied by an amelioration of AOPPs and lipid peroxidation. The mild hyperhomocysteinaemia was not influenced.
In conclusion, it is suggested that the improved antioxidative defence is involved in the beneficial action of the ACEI ramipril.
